Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

Fig. 4

Chidamide synergizes with apatinib to abrogate the leukemia burden and prolong the survival in an AML PDX model. A The schematic plan of the in vivo experiment of the AML PDX model. B The spleen image (left panel) and weight (right panel) from the PDX mice treated with distinct groups. C The analysis of human CD45 (hCD45) percentages in bone marrow (BM, left panel), spleen (SP, middle panel), and peripheral blood (PB, right panel) in the four different treatment groups. D Kaplan Meier curve of the primary AML PDX mice administered with Vehicle, apatinib, chidamide and the combined regimen at the planned treatment timepoints. CS055 and Combo mean chidamide and the combination of chidamide and apatinib

Back to article page